Quoin Pharmaceuticals (2EB0) Price & Analysis

0 Followers

2EB0 Stock Chart & Stats

€4.70

€0.04(1.20%)

At close: Jul 30 4:00 PM EDT

€4.70

€0.04(1.20%)

Day’s Range― - ―

52-Week Range€2.80 - €25.00

Previous CloseN/A

Volume0.00

Average Volume (3M)21.00

Market Cap

€8.41M

Enterprise Value-€1.08M

Total Cash (Recent Filing)€10.80M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta-0.13

Next Earnings

Nov 05, 2026

EPS Estimate

-1.36

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-14.89

Shares Outstanding4,804,161

10 Day Avg. Volume0

30 Day Avg. Volume21

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)1.65

Price to Sales (P/S)0.00

P/FCF Ratio-1.60

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€22.24

Price Target Upside373.27% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-5.75

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

FDA Fast Track Progress For QRX003Fast Track status can support more frequent FDA interaction and a more efficient development path for QRX003. Combined with the cleared investigational application and planned Phase 2/3 study, the designation strengthens the program’s regulatory position in an area with no approved therapy.

Positive Interim Clinical DataStatistically significant interim efficacy across multiple skin and itch endpoints, together with a favorable safety profile, provides meaningful clinical validation for QRX003. If sustained in larger studies, these results could support regulatory progress and differentiation in an ultra-rare disease with substantial unmet need.

Financing Extends Clinical RunwayExpected funding into the second half of 2029 gives Quoin greater capacity to conduct QRX003 development without an immediate financing requirement. The extended runway supports continuity through planned clinical work, although the securities issued may still create shareholder dilution over time.

Bears Say

No Revenue And Widening LossesQuoin remains entirely dependent on advancing development assets rather than generating commercial sales, while losses are worsening. The absence of revenue means future financial performance depends on clinical and regulatory success, leaving limited internal funding capacity until a product is approved and commercialized.

Accelerating Cash BurnAccelerating cash outflows increase the amount of capital required to sustain research and clinical programs. Even with recent financing, persistent negative operating and free cash flow means Quoin must continue converting external capital into development progress, creating ongoing funding and execution pressure.

Shrinking Equity And Asset BaseThe sharp contraction in equity and assets reflects cumulative losses and reduces the company’s financial cushion. Although no debt is reported, continued erosion of the balance sheet can constrain flexibility, increase reliance on equity financing, and amplify dilution risk if development spending remains high.

Quoin Pharmaceuticals News

Quoin Pharmaceuticals initiated with a Buy at Lake Street

Lake Street analyst Thomas Flaten initiated coverage of Quoin Pharmaceuticals (QNRX) with a Buy rating and $20 price...

16d ago

QNRX

Quoin Pharmaceuticals announces U.S. FDA granted FTD to QRX003

Quoin Pharmaceuticals (QNRX) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD,...

17d ago

QNRX

Quoin Pharmaceuticals registers to sell 9.37M ADRs for holders

This filing relates to the offer and sale from time to time by the selling stockholders of up...

21d ago

QNRX

Four Small-Cap Stocks Report New Developments (CHGA, QNRX, MYSE, LNKS)

Naples, United States, September 24th, 2026, FinanceWire Change Agents Corp. (Nasdaq:CHGA) develops agentic AI software, meaning AI tools...

15d ago

CHGA

LNKS

Quoin Gains FDA Fast Track for QRX003 Skin Therapy

Quoin Pharmaceuticals ( ($QNRX) ) just unveiled an announcement. On Sept. 22, 2026, Quoin Pharmaceuticals announced that the...

17d ago

QNRX

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Ashburn, Virginia, September 22nd, 2026, FinanceWire – First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy – Second...

17d ago

QNRX

Quoin Pharmaceuticals Gains FDA Rare Pediatric Designation

Quoin Pharmaceuticals ( ($QNRX) ) has issued an update. On September 8, 2026, Quoin Pharmaceuticals reported that the...

29d ago

QNRX

Quoin Pharmaceuticals granted Rare Pediatric Disease Designation for QRX003

Quoin Pharmaceuticals (QNRX) announced that the FDA has granted Rare Pediatric Disease Designation for the company’s lead asset,...

1M ago

QNRX

Quoin Reports Positive Interim QRX003 Netherton Data

Quoin Pharmaceuticals ( ($QNRX) ) just unveiled an update. On August 27, 2026, Quoin Pharmaceuticals entered into a...

1M ago

QNRX

Quoin Pharmaceuticals announces $50M private placement

Quoin Pharmaceuticals (QNRX) announced that it has entered into a securities purchase agreement with new and existing healthcare-focused...

1M ago

QNRX

Quoin Pharmaceuticals reports ‘positive’ data from Phase 2/3 study of QRX003

Quoin Pharmaceuticals (QNRX) announced positive interim results from CL-QRX003-004, its ongoing Phase 2/3 study of QRX003 4% lotion...

1M ago

QNRX

Quoin Pharmaceuticals Shareholders Approve Governance and Compensation Changes

Quoin Pharmaceuticals ( ($QNRX) ) has provided an announcement. At its 2026 Annual General Meeting of Shareholders held...

2M ago

QNRX

Quoin Pharmaceuticals reports Q2 EPS ($1.90), consensus ($1.77)

“The second quarter was a highly productive period across both of our delivery technology platforms,” said Michael Myers,...

2M ago

QNRX

QNRX Upcoming Earnings Report: What to Expect?

Quoin Pharmaceuticals Ltd (QNRX) is scheduled to report 2nd quarter earnings on 08/14/2026, before the market opens. Regarding...

2M ago

QNRX

2EB0 FAQ

What was Quoin Pharmaceuticals’s price range in the past 12 months?

Quoin Pharmaceuticals lowest stock price was €2.80 and its highest was €25.00 in the past 12 months.

What is Quoin Pharmaceuticals’s market cap?

Quoin Pharmaceuticals’s market cap is €8.41M.

When is Quoin Pharmaceuticals’s upcoming earnings report date?

Quoin Pharmaceuticals’s upcoming earnings report date is Nov 05, 2026 which is in 27 days.

How were Quoin Pharmaceuticals’s earnings last quarter?

Quoin Pharmaceuticals released its earnings results on Aug 14, 2026. The company reported -€1.692 earnings per share for the quarter, missing the consensus estimate of -€1.434 by -€0.258.

Is Quoin Pharmaceuticals overvalued?

According to Wall Street analysts Quoin Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Quoin Pharmaceuticals pay dividends?

Quoin Pharmaceuticals does not currently pay dividends.

What is Quoin Pharmaceuticals’s EPS estimate?

Quoin Pharmaceuticals’s EPS estimate is -1.36.

How many shares outstanding does Quoin Pharmaceuticals have?

Quoin Pharmaceuticals has 4,804,161 shares outstanding.

What happened to Quoin Pharmaceuticals’s price movement after its last earnings report?

Quoin Pharmaceuticals reported an EPS of -€1.692 in its last earnings report, missing expectations of -€1.434. Following the earnings report the stock price went up 6.092%.

Which hedge fund is a major shareholder of Quoin Pharmaceuticals?

Currently, no hedge funds are holding shares in DE:2EB0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.

Quoin Pharmaceuticals (2EB0) Earnings & Revenues

Historic Earnings Reports

2EB0 Stock 12 Month Forecast

Average Price Target

€22.24

▲(373.27% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","17":"€17","32":"€32","9.5":"€9.5","24.5":"€24.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31.1408958,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€31.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.243497,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€22.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.7947976,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€17.79</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,9.5,17,24.5,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.66,5.773915061538462,7.887830123076923,10.001745184615384,12.115660246153846,14.229575307692308,16.343490369230768,18.457405430769228,20.57132049230769,22.68523555384615,24.799150615384615,26.913065676923075,29.026980738461535,{"y":31.1408958,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.66,5.08949976923077,6.518999538461539,7.948499307692308,9.377999076923079,10.807498846153848,12.236998615384616,13.666498384615386,15.095998153846155,16.525497923076927,17.954997692307693,19.384497461538466,20.813997230769232,{"y":22.243497,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.66,4.747292123076923,5.834584246153846,6.92187636923077,8.009168492307692,9.096460615384615,10.18375273846154,11.271044861538462,12.358336984615384,13.445629107692307,14.53292123076923,15.620213353846154,16.707505476923075,{"y":17.7947976,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.92,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.66,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.35,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.75,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.08,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.88,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.86,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.7,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.66,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >